Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by iA Global Asset Management Inc.

iA Global Asset Management Inc. increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 5,383.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,030 shares of the medical research company's stock after acquiring an additional 22,610 shares during the quarter. iA Global Asset Management Inc.'s holdings in Charles River Laboratories International were worth $4,536,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Wellington Management Group LLP raised its stake in shares of Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock worth $736,819,000 after acquiring an additional 3,738,018 shares in the last quarter. State Street Corp grew its position in Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock worth $419,601,000 after purchasing an additional 41,421 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC grew its position in Charles River Laboratories International by 1.7% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company's stock worth $394,359,000 after purchasing an additional 31,359 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Charles River Laboratories International by 40.7% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,760,781 shares of the medical research company's stock worth $346,821,000 after purchasing an additional 509,163 shares during the last quarter. Finally, Earnest Partners LLC grew its position in Charles River Laboratories International by 12.4% during the 2nd quarter. Earnest Partners LLC now owns 1,004,486 shares of the medical research company's stock worth $207,507,000 after purchasing an additional 110,725 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CRL. CLSA downgraded shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. Citigroup downgraded shares of Charles River Laboratories International from a "neutral" rating to a "sell" rating and dropped their target price for the stock from $215.00 to $175.00 in a research report on Tuesday, October 1st. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They set a "sell" rating and a $151.00 target price on the stock. Robert W. Baird dropped their price objective on shares of Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating on the stock in a report on Friday, September 20th. Finally, TD Cowen raised their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a report on Monday, November 11th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and a consensus target price of $214.38.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL traded up $0.27 during trading on Friday, reaching $191.81. 624,664 shares of the company's stock traded hands, compared to its average volume of 639,601. Charles River Laboratories International, Inc. has a fifty-two week low of $176.48 and a fifty-two week high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The firm has a market cap of $9.81 billion, a PE ratio of 24.01, a P/E/G ratio of 5.15 and a beta of 1.38. The company has a 50-day simple moving average of $194.10 and a 200-day simple moving average of $203.77.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating analysts' consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International's quarterly revenue was down 1.6% compared to the same quarter last year. During the same period last year, the company posted $2.72 EPS. As a group, analysts predict that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company's stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).